Imbruvica (ibrutinib) reduced the risk of progression or death by 88 percent compared to chlorambucil in patients with chronic lymphocytic l...
259
0Like
Even as the US Food and Drug Administration (FDA) approved new agents for multiple myeloma and some lymphomas, stem cell transplant remains ...
197
0Like